Tata Motors MD calls for collaboration among stakeholders amid COVID-19 crisis

Tata Motors MD and CEO Guenter Butschek stated that the COVID-19 pandemic hit the industry at a time when it was managing the transition from the BS-IV fuel emission norms to BS-VI in a new fiscal while battling the extremely low activity and subdued demand in 2019-20.

PTI

September 05, 2020 / 20:42 IST

Representative Image

Calling for a collaborative approach among stakeholders, Tata Motors MD and CEO Guenter Butschek on September 5 said there are new challenges for the automotive industry in the restart phase of the economy.

"Now that we are in the restart phase, new challenges like growing virus cases and acute shortage of labour have come up. The end of the lockdown doesn't necessarily mean that we are post-COVID because it is still there, it can possibly create more intermittent disruptions," Butschek said.

He was speaking at the 60th annual convention of the Automotive Component Manufacturers Association of India (ACMA) in New Delhi on September 5 .

Stating that COVID-19 has placed extraordinary, unprecedented demand on the industry, he stated that the pandemic hit the industry at a time when it was managing the transition from the BS-IV fuel emission norms to BS-VI in a new fiscal while battling the extremely low activity and subdued demand in 2019-20.

The impact has been nothing short than devastating, he added.

COVID-19 Vaccine

Frequently Asked Questions

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

Show